Navigation Links
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC
Date:7/29/2014

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders.  As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.

"We are excited to move ImmunoClin's head office to Washington, D.C.  The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan.  Further, under the oversight of officer and director, Chad Johnson, the Washington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corporation.

"Washington, D.C. is a great location for the Company's principal office.  ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel.  "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."

About ImmunoClin Corporation

ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France -- and principal corporate office being established in Washington, D.C., USA. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.  ImmunoClin holds multiple patents and trademarks on a global basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.

ImmunoClin Corporation
Dr. Dorothy Bray, Director, President & CEO
www.immunoclin.com
dorothy.bray@immunoclin.com
Tel: 1.888.267.1175

Investment Inquiries
J. Scott Munro, CFO
scott.munro@immunoclin.com 
Cell: +1 778-987-4308


'/>"/>
SOURCE ImmunoClin Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
2. China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy
3. United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014
4. Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington
5. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
6. ETEX Corporation announces appointment of Stephen R. La Neve as President and Chief Executive Officer
7. Patient Safety Technologies, Inc. Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $2.22 Per Common Share in Cash
8. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricityâ„¢ products, ... Centricity EMR. These new integrations ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):